Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Other Non-Current Assets (2020 - 2026)

Core Scientific has reported Other Non-Current Assets over the past 7 years, most recently at $83.2 million for Q1 2026.

  • Quarterly results put Other Non-Current Assets at $83.2 million for Q1 2026, up 171.11% from a year ago — trailing twelve months through Mar 2026 was $83.2 million (up 171.11% YoY), and the annual figure for FY2025 was $50.3 million, up 109.34%.
  • Other Non-Current Assets reached $83.2 million in Q1 2026 per CORZ's latest filing, up from $50.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $83.2 million in Q1 2026 and bottomed at $9.3 million in Q2 2023.
  • Median Other Non-Current Assets over the past 5 years was $18.8 million (2024), compared with a mean of $26.5 million.
  • The largest annual shift saw Other Non-Current Assets crashed 55.88% in 2023 before it soared 171.11% in 2026.
  • Over 5 years, Other Non-Current Assets stood at $9.3 million in 2022, then skyrocketed by 134.7% to $21.9 million in 2023, then grew by 9.94% to $24.0 million in 2024, then soared by 109.34% to $50.3 million in 2025, then skyrocketed by 65.39% to $83.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for CORZ at $83.2 million in Q1 2026, $50.3 million in Q4 2025, and $48.4 million in Q3 2025.